tyc7111cc太阳成集团

洞察市场格局
解锁药品研发情报

免费客服电话

18983288589
医药数据查询

【药海共潮、创新共舞】2023药物研发论坛暨中关村生命科学园发展论坛

【药海共潮、创新共舞】2023药物研发论坛暨中关村生命科学园发展论坛

热度247
北京市 | 北京中关村生命科学园•泰康研修院图书馆
2023-11-19 09:002023-11-19 17:20
会议已结束
会议邀请

大会详情

  • 大会嘉宾
  • 大会日程
  • 主办单位
  • 承办单位
  • 商务合作
  • 参会联系

大会嘉宾

\u9648\u5217\u5e73\u535a\u58eb\u662f\u4e00\u540d\u514d\u75ab\u5b66\u5bb6\uff0c\u4e3b\u8981\u4ece\u4e8b\u57fa\u7840T\u7ec6\u80de\u751f\u7269\u5b66\u3001\u764c\u75c7\u514d\u75ab\u5b66\u548c\u8f6c\u5316\u7814\u7a76\uff0c\u4ee5\u53ca\u5f00\u53d1\u7528\u4e8e\u6cbb\u7597\u5305\u62ec\u764c\u75c7\u5728\u5185\u7684\u4eba\u7c7b\u75be\u75c5\u7684\u8f6c\u5316\u7814\u7a76\u3002\u5728\u52a0\u5165\u8036\u9c81\u5927\u5b66\u4e4b\u524d\uff0c\u4ed6\u66fe\u5728\u4efb\u7ea6\u7ff0\u970d\u666e\u91d1\u65af\u5927\u5b66\u533b\u5b66\u9662\u548c\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\u4efb\u6559\uff0c\u5e76\u5728\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\u5236\u836f\u7814\u7a76\u6240\u62c5\u4efb\u79d1\u5b66\u5bb6\u3002<\/span><\/div>
\u9648\u535a\u58eb\u53d1\u8868\u4e86370\u591a\u7bc7\u7ecf\u540c\u884c\u8bc4\u5ba1\u7684\u7814\u7a76\u6587\u7ae0\u3002\u4ed6\u5728\u53d1\u73b0\u7528\u4e8e\u764c\u75c7\u514d\u75ab\u7597\u6cd5\u7684 PD-1\/PD-L1 \u901a\u8def\u65b9\u9762\u7684\u5de5\u4f5c\u88ab\u300aScience\u300b\u6742\u5fd7\u8bc4\u4e3a2013\u5e74\u7684\u5e74\u5ea6\u6700\u5177\u7a81\u7834\u7814\u7a76\u5956\uff0c\u4ed6\u662f\u7f8e\u56fd\u56fd\u5bb6\u79d1\u5b66\u9662\u9662\u58eb\u3001\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u548c\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u534f\u4f1a\u4f1a\u5458\u3002<\/span><\/div>
Dr. Lieping Chen is an immunologist interested in basic T cell biology, cancer immunology, and translational research to develop new treatments for human diseases including cancer. Prior to joining Yale, he was a faculty member at Johns Hopkins University School of Medicine and Mayo Clinic, and a scientist in Bristol-Myers Squibb Pharmaceutical Research Institute.<\/span><\/div>
Dr. Chen has published over 370 peer-reviewed research articles. His work in the discovery of the PD-1\/PD-L1 pathway for cancer immunotherapy was cited as the #1 breakthrough of the year by Science magazine in 2013. He is a member of the National Academy of Sciences and a fellow of the American Association for Cancer Research and the Society for Immunotherapy of Cancer.<\/span><\/div>

<\/div>","name":"Lieping Chen","phone":null,"company":"\u8036\u9c81\u5927\u5b66","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202310\/11\/81a92bf420cdc10f616389c64144d475.png","professional":1})">
Lieping Chen - 教授
耶鲁大学
\u9648\u51b0\u5148\u751f\u73b0\u4efb\u963f\u65af\u5229\u5eb7\u4e2d\u56fd\u526f\u603b\u88c1\uff0c\u56fd\u9645\u4e1a\u52a1\u62d3\u5c55\u5408\u4f5c\u4e0e\u6218\u7565\u6295\u8d44\u8d1f\u8d23\u4eba\u3002\u4f5c\u4e3a\u4e2d\u56fd\u7ba1\u7406\u56e2\u961f\u6210\u5458\uff0c\u4ed6\u76f4\u63a5\u5411\u963f\u65af\u5229\u5eb7\u4e2d\u56fd\u603b\u7ecf\u7406\u8d56\u660e\u9686\u6c47\u62a5\u3002\u6b64\u5916\uff0c\u4ed6\u8fd8\u662f\u963f\u65af\u5229\u5eb7\u56fd\u9645\u4e1a\u52a1\u90e8iBD hub\u8d1f\u8d23\u4eba\uff0c\u9886\u5bfc\u56e2\u961f\u52a9\u529b\u4f18\u79c0\u672c\u571f\u533b\u836f\u56fd\u9645\u5316\u53d1\u5c55\uff0c\u5e76\u52a0\u6df1\u963f\u65af\u5229\u5eb7\u56fd\u9645\u4e1a\u52a1\u4e0e\u4e2d\u56fd\u4e1a\u52a1\u53d1\u5c55\u7684\u53cc\u5411\u5408\u4f5c\u3002<\/div>
\u9648\u51b0\u5148\u751f\u540c\u65f6\u517c\u4efb\u963f\u65af\u5229\u5eb7\u4e2d\u91d1\u533b\u7597\u4ea7\u4e1a\u57fa\u91d1\u521b\u59cb\u7ba1\u7406\u5408\u4f19\u4eba\uff0c\u643a\u624b\u6218\u7565\u4f19\u4f34\u4e2d\u91d1\u8d44\u672c\uff0c\u81f4\u529b\u4e8e\u4ece\u8d44\u672c\u5230\u5546\u4e1a\u5316\u591a\u65b9\u4f4d\u8d4b\u80fd\u672c\u571f\u533b\u836f\u521b\u65b0\u3002\u76ee\u524d\uff0c\u8be5\u57fa\u91d1\u5728\u7ba1\u91d1\u989d\u5df2\u8d8530\u4ebf\u5143\u4eba\u6c11\u5e01\u3002<\/div>
\u9648\u51b0\u5148\u751f\u4e8e2013\u5e745\u6708\u52a0\u5165\u963f\u65af\u5229\u5eb7\uff0c\u5386\u4efb\u6d88\u547c\u9ebb\u4e1a\u52a1\u90e8\u5e02\u573a\u603b\u76d1\u3001\u6d59\u8d63\u533a\u57df\u9500\u552e\u603b\u76d1\u53ca\u547c\u5438\u3001\u708e\u75c7\u53ca\u81ea\u4f53\u514d\u75ab\u90e8\u5e02\u573a\u6267\u884c\u603b\u76d1\u30022017\u5e74\uff0c\u4ed6\u6b63\u5f0f\u5347\u4efb\u963f\u65af\u5229\u5eb7\u4e2d\u56fd\u526f\u603b\u88c1\u3001\u6218\u7565\u5408\u4f5c\u4e0e\u4e1a\u52a1\u53d1\u5c55\u90e8\u8d1f\u8d23\u4eba\u3002\u5728\u6b64\u5c97\u4f4d\u4e0a\uff0c\u9648\u51b0\u5148\u751f\u7528\u5176\u4e30\u5bcc\u7684\u884c\u4e1a\u7ecf\u9a8c\u53ca\u654f\u9510\u7684\u5546\u4e1a\u5224\u65ad\u529b\u4e3a\u6218\u7565\u5408\u4f5c\u53ca\u5916\u90e8\u5408\u4f5c\u9879\u76ee\u5e26\u6765\u65b0\u7684\u9886\u5bfc\u529b\u548c\u65b0\u89c6\u91ce\u6210\u529f\u5e26\u9886\u56e2\u961f\u5b8c\u6210\u4e86\u591a\u9879\u4e0e\u56fd\u5185\u5916\u533b\u836f\u4f01\u4e1a\u7684\u6218\u7565\u5408\u4f5c\uff0c\u6301\u7eed\u52a9\u529b\u4e1a\u52a1\u589e\u957f\u3002<\/div>
\u9648\u51b0\u5148\u751f\u62e5\u6709\u4e30\u5bcc\u7684\u8de8\u56fd\u3001\u8de8\u884c\u4e1a\u7684\u591a\u5143\u5316\u7ecf\u9a8c\u3002\u5728\u52a0\u5165\u963f\u65af\u5229\u5eb7\u4e4b\u524d\uff0c\u4ed6\u66fe\u5728\u9ea6\u80af\u9521\u516c\u53f8\u670d\u52a1\u8fd17\u5e74\uff0c\u4efb\u5927\u4e2d\u534e\u533a\u5168\u7403\u526f\u8463\u4e8b\uff0c\u4e13\u6ce8\u4e8e\u533b\u7597\u5065\u5eb7\u53ca\u5176\u4ed6\u76f8\u5173\u884c\u4e1a\u7684\u6218\u7565\u54a8\u8be2\u5de5\u4f5c\uff0c\u4e1a\u52a1\u8303\u56f4\u6db5\u76d6\u533b\u836f\u884c\u4e1a\u6574\u4e2a\u4ea7\u4e1a\u94fe\u3002\u5728\u8fdb\u5165\u6218\u7565\u54a8\u8be2\u548c\u533b\u836f\u884c\u4e1a\u4e4b\u524d\uff0c\u4ed6\u66fe\u5728\u5317\u7f8e\u6709\u5341\u591a\u5e74\u7684\u5de5\u4f5c\u5b66\u4e60\u751f\u6d3b\u7ecf\u5386\uff0c\u5e76\u81f4\u529b\u4e8eIT\u548c\u4e92\u8054\u7f51\u76f8\u5173\u7684\u521d\u521b\u4f01\u4e1a\u5de5\u4f5c\u3002<\/div>
\u9648\u51b0\u5148\u751f\u62e5\u6709\u52a0\u62ff\u5927\u82f1\u5c5e\u54e5\u4f26\u6bd4\u4e9a\u5927\u5b66\u7535\u5b50\u53ca\u8ba1\u7b97\u673a\u5de5\u7a0b\u5b66\u5b66\u58eb\u5b66\u4f4d\uff0c\u4ee5\u53ca\u9ebb\u7701\u7406\u5de5\u5927\u5b66\u65af\u9686\u5546\u5b66\u9662\u7ba1\u7406\u5b66\u7855\u58eb\u5b66\u4f4d\u3002<\/div>

<\/div>
Mr. Chen Bing is currently VP of AstraZeneca China, Head of International Business Development and Venture Fund of AstraZeneca China. As a member of China Senior Management Team, he reports directly to Michael Lai, General Manager of AstraZeneca China. He is also in charge of the iBD hub in the international region of AstraZeneca, leading the team to drive the internationalization of top-tier local pharmaceutical companies and deepen the two-way collaborations between AstraZeneca\u2019s business development in international region and China market.<\/div>
Mr. Chen Bing serves concurrently as the Managing director and Co-founder of AZ-CICC Healthcare Investment Fund. Joining hands with the strategic partner, CICC Capital, he has been committed to empowering the innovation of local pharmaceutical companies including capital and commercialization. So far, the fund has managed a total amount of over 3 billion yuan.<\/div>
Bing joined AstraZeneca China in May 2013 and subsequently held various roles including Marketing Director, Regional Sales Director (Zhejiang and Jiangxi provinces) of GRA BU, and Executive Marketing Director of RIA BU. Since July 2017, he has been officially promoted to VP of AstraZeneca China, Head of Alliances and Business Development. In this position, Mr. Chen Bing has brought new leadership and vision to strategic cooperation and external partnership projects with his rich industrial experience and business insights, and successfully led the team to complete a number of strategic cooperation with domestic and international pharmaceutical enterprises, which has helped drive business growth continuously.<\/div>
Bing possesses a wealth of multinational and cross-sector experience. Prior to joining AstraZeneca, he served at McKinsey & Company for almost seven years, as Associate Principal, Greater China, specializing in strategic consulting for healthcare and other related industries, the scope of his work spanning the entire healthcare value chain. Prior to joining McKinsey, he lived in North America for over 10 years where his focus was on IT- and Internet-related start-ups.<\/div>
Bing holds a Bachelor\u2019s degree in Electrical and Computer Engineering from the University of British Columbia, and an MBA from MIT Sloan School of Management. <\/div>","name":"\u9648\u51b0","phone":null,"company":"\u963f\u65af\u5229\u5eb7","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202310\/28\/6acf83304d3b4fd3dd5430502020e74f.png","professional":1})">
陈冰 - 中国副总裁
阿斯利康
\u674e\u5b81\uff0c\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662\u80bf\u7624\u533b\u9662\u526f\u9662\u957f\uff0c\u4e3b\u4efb\u533b\u5e08\uff0c\u6559\u6388\uff0c\u535a\u58eb\u751f\u5bfc\u5e08\uff0c\u4e34\u5e8a\u7814\u7a76\u56fd\u5bb6\u7ea7\u8d28\u91cf\u8bc4\u4ef7\u548c\u4fc3\u8fdb\u4e2d\u5fc3\u5e38\u52a1\u526f\u4e3b\u4efb\uff0c\u4e2d\u56fd\u533b\u7597\u5668\u68b0\u884c\u4e1a\u534f\u4f1a\u4e34\u5e8a\u8bd5\u9a8c\u5206\u4f1a\u526f\u4e3b\u4efb\u59d4\u5458\uff0c\u5317\u4eac\u80bf\u7624\u5b66\u4f1a\u526f\u7406\u4e8b\u957f\u517c\u79d8\u4e66\u957f\u30022005\u5e74\u535a\u58eb\u6bd5\u4e1a\u4e8e\u4e2d\u56fd\u534f\u548c\u533b\u79d1\u5927\u5b66\u516b\u5e74\u5236\u76f4\u535a\u4e34\u5e8a\u533b\u5b66\u4e13\u4e1a\uff1b2011\u5e74\u5728\u7f8e\u56fd\u54c8\u4f5b\u5927\u5b66\u533b\u5b66\u9662\u5b66\u4e60\u80bf\u7624\u514d\u75ab\u3001\u9776\u5411\u3001\u57fa\u56e0\u6cbb\u7597\uff1b\u5c06\u56fd\u9645\u6700\u65b0\u80bf\u7624\u6cbb\u7597\u65b9\u6cd5\u548c\u7406\u5ff5\u5f15\u8fdb\u56fd\u5185\uff0c\u7275\u5934\u8fdb\u884c\u591a\u79cd\u65b0\u578b\u836f\u7269\u548c\u6cbb\u7597\u65b9\u6cd5\u7684\u7814\u7a76\uff0c\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662\u4e34\u5e8a\u7814\u7a76\uff08GCP\uff09\u5e73\u53f0\u5efa\u8bbe\u9996\u5e2d\u4e13\u5bb6\u3002\u4e13\u6ce8\u4e8e\u6297\u80bf\u7624\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u7f55\u89c1\u80bf\u7624\u7684\u4e2a\u4f53\u5316\u7cbe\u51c6\u6cbb\u7597\uff0c\u80ba\u764c\u7684\u5916\u79d1\u53ca\u56f4\u624b\u672f\u671f\u9776\u5411\u548c\u514d\u75ab\u6cbb\u7597\uff0c\u6076\u6027\u5b9e\u4f53\u80bf\u7624\u7684\u591a\u5b66\u79d1\u7cbe\u51c6\u6cbb\u7597\uff0c\u7ec6\u80de\u548c\u57fa\u56e0\u6cbb\u7597\uff0c\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c\u8f6c\u5316\u7814\u7a76\u3002\u4ee5\u901a\u8baf\u4f5c\u8005\u5728Lancet Oncology\uff0cJAMA Oncology\uff0cCancer Cell\uff0cNature\u5b50\u520a\uff0cJournal of Thoracic Oncology\u7b49\u520a\u7269\u4e0a\u53d1\u8868\u80bf\u7624\u4e13\u4e1a\u5b66\u672f\u6587\u7ae0\u4e94\u5341\u4f59\u7bc7\uff0c\u603b\u5f71\u54cd\u56e0\u5b50500\u4f59\u5206\u3002\u62c5\u4efb\u56fd\u5bb6973\u9879\u76ee\u5206\u8bfe\u9898\u8d1f\u8d23\u4eba\uff0c\u56fd\u5bb6\u91cd\u70b9\u7814\u53d1\u8ba1\u5212\u7cbe\u51c6\u533b\u5b66\u4e13\u9879\uff0c\u56fd\u5bb6\u81ea\u7136\u79d1\u5b66\u57fa\u91d1\uff0c\u4e34\u5e8a\u8bd5\u9a8c\u80fd\u529b\u63d0\u5347\uff08GCP\uff09\u5e73\u53f0\u5efa\u8bbe\u7b49\u7814\u7a76\u9879\u76ee\u8d1f\u8d23\u4eba\u3002\u9996\u521b\u9488\u5bf9\u6bcf\u4e00\u4f4d\u60a3\u8005\u91c7\u7528\u7cbe\u51c6\u5206\u5b50\u8bca\u65ad\uff0c\u4e2a\u4f53\u5316\u5236\u5b9a\u9002\u5b9c\u7684\u9776\u5411\u3001\u7ec6\u80de\u3001\u6297\u4f53\u3001\u7eb3\u7c73\u3001\u75ab\u82d7\u7b49\u65b0\u65b9\u6cd5\u7528\u4ee5\u6cbb\u7597\u96be\u6cbb\u3001\u590d\u53d1\u3001\u6cbb\u7597\u5931\u8d25\u80bf\u7624\u60a3\u8005\u7684\u8bca\u7597\u4f53\u7cfb\uff0c\u83b7\u5f97\u56fd\u9645\u8ba4\u53ef\u3002<\/div>
Li Ning, Vice President of Cancer Hospital Chinese Academy of Medical Sciences, Chief Physician, Professor, Doctoral Supervisor, Executive Deputy Director of National Center for Quality Evaluation and Promotion of Clinical Research, Deputy Director of Clinical Trial Branch of China Association for Medical Devices Industry (CAMDI), Vice President and Secretary General of Beijing association of oncology. 2005, he obtained his doctoral degree in Clinical Medicine from Peking Union Medical College through an eight-year program. 2011, he studied tumor immunology, targeting, and gene therapy at Harvard Medical School. He has introduced the latest international methods and concepts of cancer treatment into the country, leading research on various new drugs and treatment methods. He is the chief expert in the construction of the Clinical Research (GCP) platform at the Chinese Academy of Medical Sciences.<\/div>
He focuses on clinical trials of anti-tumor new drugs, personalized precision treatment for rare tumors, surgical and perioperative targeted and immunotherapy for lung cancer, multidisciplinary precision treatment for malignant solid tumors, cell and gene therapy, and translational research of new drug clinical trials.He has published over 50 academic articles in various important academic journals in the field of oncology, including Lancet Oncology, JAMA Oncology, Cancer Cell, Nature sub-journals, Journal of Thoracic Oncology, etc. The total impact factor of these articles exceeds 500. He serves as the principal investigator of a sub-project of the National 973 Project, the leader of the National Key Research and Development Program for Precision Medicine, the National Natural Science Foundation of China, and the Clinical Trial Capability Enhancement (GCP) Platform, among other research projects. He has pioneered the use of precise molecular diagnosis for each patient and personalized the appropriate methods such as targeted therapy, cell therapy, antibody therapy, nanotechnology, and vaccines for the treatment of refractory, recurrent, and treatment-failed cancer patients. This diagnostic and treatment system has gained international recognition.<\/div>","name":"\u674e\u5b81","phone":null,"company":"\u56fd\u5bb6\u764c\u75c7\u4e2d\u5fc3\u00b7\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662\u80bf\u7624\u533b\u9662","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202310\/17\/54e61aeb61decdc91a189e1e2d30ec36.png","professional":1})">
李宁 - 副院长
国家癌症中心·中国医学科学院肿瘤医院
Clive Svendsen\u535a\u58eb\u662f\u897f\u8fbe-\u8d5b\u5948\u518d\u751f\u533b\u5b66\u7814\u7a76\u6240(RMI)\u7684\u521b\u59cb\u4eba\uff0c\u8be5\u7814\u7a76\u6240\u62e5\u670930\u591a\u540d\u6559\u804c\u5458\u5de5\u3002svensen\u535a\u58eb\u7684\u5b9e\u9a8c\u5ba4\u4e13\u6ce8\u4e8e\u4f7f\u7528\u4eba\u7c7b\u8bf1\u5bfc\u591a\u80fd\u5e72\u7ec6\u80de\u6765\u6a21\u62df\u5404\u79cd\u795e\u7ecf\u7cfb\u7edf\u75be\u75c5\u3002\u4ed6\u7684\u5b9e\u9a8c\u5ba4\u7684\u53e6\u4e00\u4e2a\u91cd\u70b9\u662f\u4f7f\u7528\u5e72\u7ec6\u80de\u548c\u751f\u957f\u56e0\u5b50\u7ec4\u5408\u7684\u5c16\u7aef\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/div>
Dr. Clive Svendsen is the founder of the Cedars-Sinai Board of Governors Regenerative Medicine Institute (RMI) with over 30 faculty members. Dr. Svendsen\u2019s lab focuses on using human induced pluripotent stem cells to model a wide range of neurological diseases. The other focus of his lab is cutting-edge clinical trials using combinations of stem cells and growth factors.<\/div>

<\/div>

<\/div>","name":"Clive Svendsen","phone":null,"company":"\u897f\u8fbe-\u8d5b\u5948\u518d\u751f\u533b\u5b66\u7814\u7a76\u6240","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202310\/17\/6a6cbfc5ea887122b5283d1a9333b2c6.png","professional":1})">
Clive Svendsen - 主任
西达-赛奈再生医学研究所
\u738b\u5174\u5229\u535a\u58eb\uff0c\u4e8e2023\u5e741\u6708\u52a0\u5165\u590d\u661f\u533b\u836f\u96c6\u56e2\uff0c\u73b0\u4efb\u590d\u661f\u533b\u836f\uff08\u80a1\u7968\u4ee3\u7801\uff1a600196.SH\uff1b 02196.HK\uff09\u6267\u884c\u603b\u88c1\uff0c\u4ea6\u517c\u4efb\u590d\u661f\u533b\u836f\u521b\u65b0\u836f\u4e8b\u4e1a\u90e8\u8054\u5e2d\u9996\u5e2d\u6267\u884c\u5b98\uff08\u8054\u5e2dCEO\uff09\u3001\u5168\u7403\u7814\u53d1\u4e2d\u5fc3\u9996\u5e2d\u6267\u884c\u5b98\uff08CEO\uff09\u3002\u52a0\u5165\u590d\u661f\u533b\u836f\u96c6\u56e2\u524d\uff0c\u738b\u535a\u58eb\u5148\u540e\u66fe\u5728\u7f8e\u56fd\u5148\u7075\u8446\u96c5, \u9ed8\u6c99\u4e1c\u3001\u8bfa\u534e\u836f\u7269\u516c\u53f8\u62c5\u4efb\u4e0d\u540c\u7684\u9886\u5bfc\u7ba1\u7406\u804c\u52a1\uff0c\u5728\u5168\u7403\u836f\u54c1\u7814\u53d1\u65b9\u9762\u5177\u6709\u4e30\u5bcc\u7ecf\u9a8c\uff0c\u5e26\u9886\u4e86\u8bf8\u591a\u5927\u578b\u5168\u7403\u4e34\u5e8a\u8bd5\u9a8c\u5e76\u6210\u529f\u63d0\u4ea4\u4e86\u591a\u9879IND\/NDA\u7533\u8bf7\u3002<\/div>
\u738b\u535a\u58eb\u83b7\u8058\u4e3a\u7f8e\u56fd\u8d1d\u52d2\u533b\u5b66\u9662\uff08Baylor College of Medicine\uff09\u7ec8\u8eab\u6559\u6388\uff0c\u66fe\u83b7\u5f97\u7f8e\u56fd\u5fc3\u8840\u7ba1\u534f\u4f1a\uff08American Heart Association\uff09\u7684\u6770\u51fa\u5b66\u8005\u5956\uff0c\u5c71\u4e1c\u5927\u5b66\u957f\u6c5f\u5b66\u8005\u53ca\u56fd\u5bb6\u7279\u8058\u6559\u6388\u3002\u540c\u65f6\uff0c\u738b\u535a\u58eb\u8fd8\u662f\u6fb3\u5927\u5229\u4e9a\u6ce8\u518c\u6267\u4e1a\u533b\u5e08\u3002\u4ed6\u7684\u5b66\u672f\u7814\u7a76\u9886\u57df\u5305\u62ec\u4e34\u5e8a\u5fc3\u8840\u7ba1\u75be\u75c5\u3001\u7fa4\u4f53\u9057\u4f20\u5b66\u3001\u5206\u5b50\u7ec6\u80de\u751f\u7269\u5b66\u7b49\uff0c\u5e76\u5df2\u5728\u56fd\u9645\u671f\u520a\u53d1\u8868220\u591a\u7bc7SCI\u6587\u7ae0\uff08\u5305\u62ecNature Medicine\u3001JCI\u3001Circulation\u3001Circulation Research\u3001PNAS\u3001Diabetes\u3001ATVB\u4ee5\u53caJBC\u7b49\uff09\u3002<\/div>

<\/div>","name":"\u738b\u5174\u5229","phone":null,"company":"\u590d\u661f\u533b\u836f","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202311\/13\/738fba9f0d24b16b70a9e536e4937bc6.jpeg","professional":1})">
王兴利 - 执行总裁
复星医药
\u3001\u674e\u950b\u535a\u58eb<\/strong>\uff0c<\/span>\u4e2d\u56fd\u7c4d\uff0c\u535a\u58eb\uff0c\u56fd\u5bb6\u4eba\u624d\u83b7\u5f97\u8005\u3002\u73b0\u4efb\u5317\u4eac\u5929\u5e7f\u5b9e\u751f\u7269\u6280\u672f\u80a1\u4efd\u6709\u9650\u516c\u53f8\u8463\u4e8b\u957f\u517c\u603b\u7ecf\u7406\u3002\u674e\u950b\u535a\u58eb\u6709\u8fd1\u5341\u5e74\u5728\u7f8e\u56fd\u751f\u7269\u533b\u836f\u7814\u53d1\u90e8\u751f\u4ea7\u5de5\u827a\u53ca\u4ea7\u4e1a\u5316\u90e8\u95e8\u7684\u7ecf\u9a8c\uff0c 2011\u5e749\u6708\u674e\u950b\u535a\u58eb\u56de\u56fd\uff0c\u5f15\u8fdb\u4e86\u6709\u7f8e\u56fd\u4ea7\u4e1a\u5316\u7ecf\u9a8c\u76844\u540d\u79d1\u5b66\u5bb6\u7ec4\u6210\u7684\u6838\u5fc3\u6280\u672f\u56e2\u961f\uff0c\u5728\u79ef\u6781\u5f15\u8fdb\u5438\u6536\u56fd\u5916\u524d\u6cbf\u6280\u672f\u7684\u540c\u65f6\uff0c\u4e00\u76f4\u575a\u6301\u81ea\u4e3b\u521b\u65b0\uff0c\u79ef\u6781\u5206\u6790\u628a\u63e1\u56fd\u9645\u6297\u4f53\u6280\u672f\u53d1\u5c55\u7684\u6700\u65b0\u8d8b\u52bf\u3002\u7ed3\u5408\u6211\u56fd\u4ea7\u4e1a\u53d1\u5c55\u7684\u5177\u4f53\u60c5\u51b5\uff0c\u5e26\u9886\u516c\u53f8\u56e2\u961f\u5efa\u7acb\u4e86\u56fd\u5185\u5c11\u6570\u62e5\u6709\u5b8c\u6574\u521b\u65b0\u6297\u4f53\u836f\u7269\u7814\u53d1\u53ca\u4ea7\u4e1a\u5316\u6280\u672f\u5e73\u53f0\u7684\u751f\u7269\u836f\u4f01\u4e4b\u4e00\uff0c\u4e3b\u8981\u4ea7\u54c1\u4e3aMIL62\u3001MIL93\u3001MBS303\u3001MBS314\u7b49\uff0c\u591a\u5e74\u6765\u79ef\u6781\u5f00\u53d1\u4e86\u5341\u4f59\u4e2a\u65e8\u5728\u6ee1\u8db3\u56fd\u5185\u60a3\u8005\u91cd\u5927\u9700\u6c42\u7684\u6297\u4f53\u4ea7\u54c1\uff0c\u4e34\u5e8a\u9002\u5e94\u75c7\u6db5\u76d6\u80ba\u764c\u3001\u6dcb\u5df4\u7624\u3001\u80c3\u764c\u3001\u72fc\u75ae\u6027\u80be\u708e\u3001\u819c\u6027\u80be\u75c5\u7b49\u591a\u4e2a\u6cbb\u7597\u9886\u57df\u3002<\/div>
\t <\/div>
\tDr. Li Feng, Chinese nationality, Ph.D., National Talent Recipient. Dr. Li is the President and General Manager of Beijing Mabworks Biotech Co.Ltd<\/span>. Dr. Li Feng has nearly a decade of experience<\/span> in the production process and industrialization department of the U.S. Biopharmaceutical R&D Department. In September 2011, Dr. Li returned to China and established<\/span> a core technology team consisting of four scientists with experience in industrialization in the U.S. While actively introducing and absorbing cutting-edge technologies from abroad, he consistently emphasized independent innovation <\/span>and has been actively analyzing and grasping the latest trends of the development of international antibody technology.<\/div>
\tcombined with the specific conditions of China's industrial development, leading the company to establish itself as one of the few domestic biopharmaceutical enterprises with a comprehensive innovative platform for antibody drug research, development, and industrialization. The company's primary<\/span> products are MIL62, MIL93, MBS303, MBS314, etc., and over the years, actively developed more than 10 antibody products d  aimed at meeting the significant needs of domestic patients. These products cover various therapeutic areas, including lung cancer, lymphoma, gastric cancer, lupus nephritis, membranous nephropathy, and more.<\/span><\/div>

<\/div>","name":"\u674e\u950b","phone":null,"company":"\u5929\u5e7f\u5b9e\u751f\u7269","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202310\/31\/477a3d4d5b7a55a7351679e68d3cb72c.png","professional":1})">
李锋 - 董事长兼总经理
天广实生物
Joshua Brody\u533b\u5b66\u535a\u58eb\u662f\u897f\u5948\u5c71Tisch\u764c\u75c7\u7814\u7a76\u6240\u6dcb\u5df4\u7624\u514d\u75ab\u6cbb\u7597\u9879\u76ee\u7684\u4e3b\u4efb\uff0c\u4e5f\u662f\u4f0a\u574e\u57fa\u56e0\u7ec4\u5b66\u7814\u7a76\u6240\u7684\u6559\u5458\u3002\u81ea\u4ed62011\u5e74\u52a0\u5165\u897f\u5948\u5c71\u533b\u9662\u4ee5\u6765\uff0c\u5c31\u53d1\u5c55\u4e86\u4e00\u4e2a\u91cd\u70b9\u4e34\u5e8a\u9879\u76ee\uff0c\u4ee5\u53ca\u4e00\u4e2a\u8f6c\u5316\u6027\u7684\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b9e\u9a8c\u5ba4\uff0c\u8be5\u5b9e\u9a8c\u5ba4\u81f4\u529b\u4e8e\u57fa\u7840\u548c\u5e94\u7528\u80bf\u7624\u514d\u75ab\u5b66\u7684\u7814\u7a76\uff0c\u4ee5\u5f00\u53d1\u65b0\u7684\u7597\u6cd5\uff0c\u5c24\u5176\u662f\u9488\u5bf9\u6dcb\u5df4\u7624\u3001\u4e73\u817a\u764c\u548c\u5934\u9888\u764c\u3002\u76f8\u5173\u7684\u7814\u7a76\u6210\u679c\u5df2\u5728\u300aNature Medicine\u300b\u548c\u300aCancer Discovery\u300b\u7b49\u9876\u7ea7\u671f\u520a\u4e0a\u53d1\u8868\u3002Joshua Brody\u533b\u5b66\u535a\u58eb\u5f00\u521b\u4e86\u4e00\u79cd\u539f\u4f4d\u75ab\u82d7\u63a5\u79cd\u7684\u65b9\u6cd5\uff0c\u8be5\u65b9\u6cd5\u5728\u80bf\u7624\u90e8\u4f4d\u8bf1\u5bfc\u6297\u80bf\u7624\u514d\u75ab\uff0c\u53ef\u5b9e\u73b0\u5168\u8eab\u80bf\u7624\u7684\u6d88\u9000\u3002\u4ed6\u8fd8\u5f00\u53d1\u4e86\u4e00\u79cd\u4e0e\u5e72\u7ec6\u80de\u79fb\u690d\u7ed3\u5408\u7684\u65b9\u6cd5\uff0c\u63d0\u9ad8\u514d\u75ab\u6cbb\u7597\u836f\u7269\u5bf9\u96be\u6cbb\u6027\u6dcb\u5df4\u7624\u7684\u7597\u6548\u3002\u8fd1\u671f\uff0c\u4ed6\u7684\u56e2\u961f\u53d1\u73b0\u4e86\u4e00\u79cd\u901a\u8fc7\u963b\u6b62\u80bf\u7624\u9003\u907fCAR-T\u548c\u53cc\u7279\u5f02\u6027\u6297\u4f53\u7597\u6cd5\u7684\u5e38\u89c1\u9003\u9038\u673a\u5236\u6765\u6539\u5584\u514d\u75ab\u7597\u6cd5\u7684\u65b0\u65b9\u6cd5\u3002<\/span><\/div>
Brody\u535a\u58eb\u7684\u7814\u7a76\u5f97\u5230\u4e86\u8bb8\u591a\u8d44\u52a9\u673a\u6784\u7684\u652f\u6301\uff0c\u5305\u62ec\u7f8e\u56fd\u56fd\u7acb\u536b\u751f\u7814\u7a76\u9662\u3001\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u3001Damon Runyon\u764c\u75c7\u7814\u7a76\u57fa\u91d1\u4f1a\u3001\u6ee4\u6ce1\u6dcb\u5df4\u7624\u7814\u7a76\u57fa\u91d1\u4f1a\u548c\u6dcb\u5df4\u7624\u7814\u7a76\u57fa\u91d1\u4f1a\u3002\u3002\u4ed6\u4e5f\u662f\u8bb8\u591a\u4e13\u4e1a\u7ec4\u7ec7\u7684\u6210\u5458\uff0c\u5305\u62ec\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a\u548c\u80bf\u7624\u5b66\u4e34\u5e8a\u8bd5\u9a8c\u8054\u76df\u3002<\/span><\/div>
Joshua Brody, MD, is the Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai and a faculty member of the Icahn Genomics Institute. Since joining Mount Sinai in 2011, he has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab which investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head\/neck cancer with results published in top-tier journals including Nature Medicine and Cancer Discovery. Dr. Brody has pioneered a therapeutic vaccine approach\u2014in situ vaccination\u2014that induces anti-tumor immunity at the tumor site and can also cause regression of tumors throughout the body. He has also developed a way to use increase the power of immunotherapy drugs against treatment-resistant lymphomas by combining them with stem cell transplantation. Recently, his group discovered a novel approach to improve immunotherapies by preventing a common escape mechanism that tumors use to evade CAR-T and bispecific antibody therapies.<\/span><\/div>
Dr. Brody\u2019s research receives funding from numerous grantors, including the National Institutes of Health, the Cancer Research Institute, the Damon Runyon Cancer Research Foundation, the Follicular Lymphoma Research Foundation and the Lymphoma Research Foundation. He is a member of many professional organizations, including the Society for the Immunotherapy of Cancer and the Alliance for Clinical Trials in Oncology.<\/span><\/div>

<\/div>","name":"Joshua Brody","phone":null,"company":"\u7f8e\u56fd\u897f\u5948\u5c71\u4f0a\u574e\u533b\u5b66\u9662","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202310\/19\/b942a920d7eafa49219af21298952d3c.png","professional":1})">
Joshua Brody - 副教授
美国西奈山伊坎医学院
Anna Cereseto\u662f\u610f\u5927\u5229\u7279\u4f26\u6258\u5927\u5b66\u7ec6\u80de\u3001\u8ba1\u7b97\u548c\u6574\u5408\u751f\u7269\u5b66\u7cfb\uff08CIBIO\uff09\u7684\u6b63\u6559\u6388\uff0c\u4e5f\u662f\u610f\u5927\u5229\u7279\u4f26\u6258\u5927\u5b66\u5206\u5b50\u75c5\u6bd2\u5b66\u5b9e\u9a8c\u5ba4\u7684\u7814\u7a76\u5c0f\u7ec4\u8d1f\u8d23\u4eba\u30021990\u5e74\uff0c\u5979\u5728\u70ed\u90a3\u4e9a\u5927\u5b66\u83b7\u5f97\u751f\u7269\u79d1\u5b66\u7855\u58eb\u5b66\u4f4d\uff1b1992\u5e74\uff0c\u5979\u83b7\u5f97\u5408\u683c\u7684\u4e13\u4e1a\u751f\u7269\u5b66\u5bb6\u8d44\u683c\u8bc1\u4e66\uff0c1997\u5e74\uff0c\u83b7\u5f97\u5206\u5b50\u751f\u7269\u5b66\u535a\u58eb\u5b66\u4f4d\u3002\u5979\u66fe\u5728\u610f\u5927\u5229\u6bd4\u8428\u7684\u9ad8\u7b49\u5e08\u8303\u5b66\u9662\u62c5\u4efb\u5206\u5b50\u751f\u7269\u5b66\u526f\u6559\u6388\uff0c\u5e76\u5728\u897f\u5948\u5c71\u533b\u5b66\u9662\u62c5\u4efb\u8bb2\u5e08\uff0c\u6b64\u5916\uff0c\u5979\u8fd8\u5728\u5eb7\u5948\u5c14\u5927\u5b66\u548c\u7f8e\u56fd\u56fd\u7acb\u536b\u751f\u7814\u7a76\u9662\uff08NIH\uff09\u7684\u56fd\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u8fdb\u884c\u4e86\u535a\u58eb\u540e\u7814\u7a76\u3002\u5979\u9886\u5bfc\u7684\u7814\u7a76\u5c0f\u7ec4\u5728\u63a8\u52a8\u57fa\u4e8eCRISPR-Cas\u7cfb\u7edf\u7684\u57fa\u56e0\u7ec4\u7f16\u8f91\u6280\u672f\u65b9\u9762\u505a\u51fa\u4e86\u91cd\u5927\u8d21\u732e\uff0c\u5e76\u8bc1\u660e\u4e86\u8fd9\u4e9b\u6280\u672f\u5728\u9006\u8f6c\u5bfc\u81f4\u6700\u5e38\u89c1\u7684\u9057\u4f20\u75be\u75c5\u4e4b\u4e00\uff0c\u56ca\u6027\u7ea4\u7ef4\u5316\u7684\u9057\u4f20\u7f3a\u9677\u65b9\u9762\u7684\u6709\u6548\u6027\u3002\u5979\u7684\u7814\u7a76\u5f97\u5230\u4e86\u6b27\u6d32\u793e\u533a\uff08Horizon 2020\uff09\u4ee5\u53ca\u7f8e\u56fd\u548c\u610f\u5927\u5229\u56ca\u6027\u7ea4\u7ef4\u5316\u57fa\u91d1\u4f1a\u7684\u652f\u6301\u3002\u622a\u81f32023\u5e743\u6708\uff0c\u5979\u5171\u53d1\u8868\/\u5408\u845765\u7bc7\u8bba\u6587\uff0c\u5728Science\u3001Nature Med\u7b49\u671f\u520a\u4e0a\u53d1\u8868\u8fc7\u8bba\u6587\uff0c\u5728\u6b27\u6d32\u548c\u7f8e\u56fd\u7684\u9006\u8f6c\u5f55\u75c5\u6bd2\u5b66\u548c\u57fa\u56e0\u7f16\u8f91\u9886\u57df\uff0c\u5979\u4e0e\u591a\u4e2a\u5b9e\u9a8c\u5ba4\u5408\u4f5c\u5f00\u5c55\u7814\u7a76\u30022019\u5e74\uff0c\u5979\u5171\u540c\u521b\u7acb\u4e86\u4e00\u5bb6\u540d\u4e3aAlia Therapeutics\u7684\u521d\u521b\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u57fa\u56e0\u7ec4\u7f16\u8f91\u6cbb\u7597\uff0c\u5979\u76ee\u524d\u62c5\u4efb\u8be5\u516c\u53f8\u7684\u521b\u59cb\u4eba\u3001\u8463\u4e8b\u548cCSO SAB\u4e3b\u5e2d\u3002<\/div>
Anna Cereseto is Full Professor of Full Professor, Department of Cellular, Computational and Integrative Biology (CIBIO) at the University of Trento and group leader of the Molecular Virology Lab at the CIBIO Department. In 1990, she obtained a Master's degree in Biological Sciences from the University of Genoa. In 1992, she qualified Professional Biologist (Esame di Stato di abilitazione all\u2019esercizio della professione di Biologo). In 1997, she obtained a doctoral degree in molecular biology. During her career she was Associate Professor of Molecular Biology at Scuola Normale Superiorein Pisa. Before that she was Instructor at the Mount SinaiSchool of Medicine and postdoctoral fellow at the CornellUniversity and at the National Cancer Institute of the NIH inBethesda.1990 Master degree in Biological. She is leading a research group that gave major contribution in advancing genome editing technologies based CRISPR-Cas systems and proved their efficacy in reversing genetic defects causing one of the most frequent genetic disease, cystic fibrosis. Her research is supported by the European Community (Horizon 2020) and by the US and Italian Cystic Fibrosis Foundations. As of March 2023, she has published\/co authored a total of 65 papers and has published papers in journals such as Science and Nature Med. In the fields of retrovirology and gene editing, she has collaborated with multiple laboratories in Europe and the United States. In 2019 she co-founded a start-up, Alia Therapeutics, working on genome editing treatments where she is currently founder, Director and CSO SAB chair.<\/div>

<\/div>","name":"Anna Cereseto","phone":null,"company":"\u610f\u5927\u5229\u7279\u4f26\u6258\u5927\u5b66\u5206\u5b50\u751f\u7269\u5b66\u5b9e\u9a8c\u5ba4","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202311\/09\/7cb87a2941ad92ba3564707c5499f8c5.png","professional":1})">
Anna Cereseto - 首席研究员、系副主任
意大利特伦托大学分子生物学实验室
Antonio Bertoletti, MD\u662f\u75c5\u6bd2\u6027\u809d\u708e\u9886\u57df\u7684\u4e13\u5bb6\uff0c\u64c5\u957f\u7814\u7a76\u4e59\u578b\u809d\u708e\uff08HBV\uff09\u611f\u67d3\u7684\u514d\u75ab\u75c5\u7406\u673a\u5236\u3002\u4ed6\u5728\u610f\u5927\u5229\u5e15\u5c14\u9a6c\u5927\u5b66\u653b\u8bfb\u533b\u5b66\u5b66\u4f4d\u671f\u95f4\u5c31\u5f00\u59cb\u4ece\u4e8b\u75c5\u6bd2\u6027\u809d\u708e\u65b9\u9762\u7684\u7814\u7a76\u30021991\u5e74\uff0c\u4ed6\u5728\u65af\u514b\u5229\u666e\u65af\u7814\u7a76\u6240\uff08\u62c9\u970d\u5229\u4e9a\uff09\u653b\u8bfb\u4f20\u67d3\u75c5\u4e13\u4e1a\u533b\u5b66\u535a\u58eb\u5b66\u4f4d\uff0c\u5728\u6b64\u671f\u95f4\uff0c\u4ed6\u82b1\u4e86\u4e24\u5e74\u65f6\u95f4\u9996\u6b21\u786e\u5b9a\u4e86\u4eba\u7c7b<\/span>\u4e59\u578b\u809d\u708e\u75c5\u6bd2<\/span>\uff08HBV\uff09\u7279\u5f02\u6027\u7ec6\u80de\u6bd2\u6027 T \u7ec6\u80de\u53cd\u5e94\u7684\u7279\u5f81\u3002\u4ed6\u56de\u5230\u5e15\u5c14\u9a6c\u5927\u5b66\uff0c\u5728\u4f20\u67d3\u75c5\u7cfb\u62c5\u4efb\u4e34\u5e8a\u79d1\u5b66\u5bb6\uff0c\u7ee7\u7eed\u7814\u7a76\u4eba\u7c7b\u4e59\u578b\u809d\u708e\u75c5\u6bd2\u7279\u5f02\u6027 T \u7ec6\u80de\u3002Bertoletti\u535a\u58eb\u4e8e1995\u5e74\u52a0\u5165\u5188\u6bd4\u4e9a\u7684MRC\u5355\u4f4d\uff0c\u62c5\u4efb\u9ad8\u7ea7\u514d\u75ab\u5b66\u5bb6\uff0c\u7814\u7a76HIV-2\u7279\u5f02\u6027T\u7ec6\u80de\u514d\u75ab\uff0c1997\u5e74\uff0c\u4ed6\u5728\u82f1\u56fd\u4f26\u6566\u5927\u5b66\u5b66\u9662\u7684 \"UCL \u809d\u75c5\u7814\u7a76\u6240 \"\u62c5\u4efb\u9ad8\u7ea7\u8bb2\u5e08\u30022006\u5e74\uff0c\u4ed6\u79fb\u5c45\u65b0\u52a0\u5761\uff0c\u73b0\u4efb\u675c\u514b\u65b0\u52a0\u5761\u56fd\u7acb\u5927\u5b66\u533b\u5b66\u9662\u65b0\u5174\u75c5\u6bd2\u6027\u75be\u75c5\u9879\u76ee\u7684\u6559\u6388\u30022015\u5e74\uff0c\u4ed6\u521b\u7acb\u4e86Lion TCR Pte\uff08http:\/\/liontcr.com\uff09\uff0c \u8fd9\u662f\u4e00\u5bb6\u751f\u7269\u6280\u672f\u516c\u53f8\uff0c\u9488\u5bf9\u75c5\u6bd2\u76f8\u5173\u764c\u75c7\uff08HBV-HCC \u548c EBV \u76f8\u5173\u6076\u6027\u80bf\u7624\uff09\u548c\u6162\u6027\u75c5\u6bd2\u611f\u67d3\u5f00\u53d1\u57fa\u4e8e\u514d\u75ab\u7684\u6cbb\u7597\u65b9\u6cd5\u3002<\/span><\/div>
\u4ed6\u76ee\u524d\u7684\u7814\u7a76\u91cd\u70b9\u662f\u5f00\u53d1\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u75c5\u6bd2\uff08HBV\uff09\u611f\u67d3\u548c\u809d\u7ec6\u80de\u764c\u7684\u65b0\u578b\u514d\u75ab\u7597\u6cd5\uff08TCR-\u5b9a\u5411 T \u7ec6\u80de\uff09\uff0c\u5e76\u5bf9\u6162\u6027HBV\u60a3\u8005\u7684\u6297\u75c5\u6bd2\u514d\u75ab\u8fdb\u884c\u8868\u5f81\u3002\u5728\u8fc7\u53bb\u7684\u4e24\u5e74\u91cc\uff0c\u81eaCOVID-19\u5927\u6d41\u884c\u5f00\u59cb\u4ee5\u6765\uff0c\u4ed6\u7684\u5b9e\u9a8c\u5ba4\u4e00\u76f4\u79ef\u6781\u53c2\u4e0e\u5bf9COVID-19\u548cSARS\u5eb7\u590d\u8005\u4ee5\u53ca\u5065\u5eb7\u4e2a\u4f53\u7684SARS-COV2\u7279\u5f02\u6027T\u7ec6\u80de\u514d\u75ab\u53cd\u5e94\u7684\u7814\u7a76\uff0c\u5e76\u5f00\u53d1\u4e86\u65b0\u7684\u65b9\u6cd5\u6765\u8868\u5f81\u5b83\u4eec\u7684T\u7ec6\u80de\u53cd\u5e94\u3002<\/span><\/div>

<\/div>
Antonio Bertoletti, MD is an expert in the field of viral hepatitis, with a specific interest in the immunopathogenesis of HBV infection. He began working in viral hepatitis as a medical student at the University of Parma (Italy). During his MD specialization (1991) in Infectious Diseases he spent two years at The Scripps Research Institute (La Jolla) characterizing for the first time the Hepatitis B virus (HBV) specific cytotoxic T cell response in man. He returned to the University of Parma, where he worked in the Department of Infectious Diseases as a Clinical Scientist continuing his study of human HBV specific T cells. Dr. Bertoletti then joined (1995) the MRC Unit in the Gambia, as Senior Immunologist, to study HIV-2 specific T cell Immunity before accepting a position of Senior Lecturer at \u201cThe UCL Institute of Hepatology\u201d at University College of London (UK) (1997).  <\/span><\/div>
In 2006 he moved to Singapore where is now Full Professor, at the Emerging Viral Disease Program at Duke-NUS Medical School. <\/span><\/div>
In 2015 he founded Lion TCR Pte (http:\/\/liontcr.com), a biotech company developing immune-based treatments for virus-related cancers (HBV-HCC and EBV related malignancies) and chronic viral infections. <\/span><\/div>
His current research is focus on the development of new immunological based therapies (TCR-redirected T cells) for the treatment of HBV chronic infection and Hepatocellular carcinoma and on the characterization of antiviral Immunity in chronic HBV patients. In the last 2 years, after the start of the COVID-19 pandemic, his laboratory has been actively involved in the characterization of SARS-COV2 specific T cell immune response in COVID-19 and SARS convalescent and healthy individuals and in the development of new methods to characterize their T cell response).<\/span><\/div>

<\/div>

<\/div>","name":"Antonio Bertoletti","phone":null,"company":"\u675c\u514b-\u65b0\u52a0\u5761\u56fd\u7acb\u5927\u5b66\u533b\u5b66\u9662","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202310\/11\/f940c1396c1a23785430a8ffc3a79982.png","professional":1})">
Antonio Bertoletti - 传染病专家
杜克-新加坡国立大学医学院
\u5d14\u9701\u677e\u535a\u58eb\u662f\u8bfa\u8bda\u5065\u534e\u533b\u836f\u6709\u9650\u516c\u53f8\uff08\u7b80\u79f0\u201c\u8bfa\u8bda\u5065\u534e\u201d\uff09\u7684\u8054\u5408\u521b\u59cb\u4eba\u3001\u8463\u4e8b\u957f\u517cCEO\u3002\u8bfa\u8bda\u5065\u534e\uff08\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a09969\uff1b\u4e0a\u4ea4\u6240\u79d1\u521b\u677f\uff1a688428\uff09\u6210\u7acb\u4e8e2015\u5e74\uff0c\u662f\u4e00\u5bb6\u5546\u4e1a\u5316\u9636\u6bb5\u7684\u751f\u7269\u533b\u836f\u9ad8\u79d1\u6280\u516c\u53f8\uff0c\u4e13\u6ce8\u4e8e\u6076\u6027\u80bf\u7624\u53ca\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u6cbb\u7597\u9886\u57df\u7684\u4e00\u7c7b\u65b0\u836f\u7814\u5236\u3002\u73b0\u6709\u591a\u4e2a\u65b0\u836f\u4ea7\u54c1\u5904\u4e8e\u5546\u4e1a\u5316\u3001\u4e34\u5e8a\u53ca\u4e34\u5e8a\u524d\u7814\u53d1\u9636\u6bb5\u3002\u516c\u53f8\u5728\u5317\u4eac\u3001\u5357\u4eac\u3001\u4e0a\u6d77\u3001\u5e7f\u5dde\u3001\u676d\u5dde\u3001\u9999\u6e2f\u548c\u7f8e\u56fd\u8bbe\u6709\u5206\u652f\u673a\u6784\u3002<\/div>
\u5d14\u535a\u58eb\u6709\u8d85\u8fc730\u5e74\u7684\u65b0\u836f\u7814\u7a76\u4e0e\u5f00\u53d1\u7ecf\u9a8c\u3002\u66fe\u5728\u7f8e\u56fd\u9ed8\u514b\u516c\u53f8\u5de5\u4f5c14\u5e74\uff0c\u62c5\u4efb\u5fc3\u8840\u7ba1\u75be\u75c5\u9886\u57df\u65e9\u671f\u836f\u7269\u7814\u53d1\u90e8\u4e3b\u5e2d\u7b49\u804c\u52a1\u3002<\/div>
\u5d14\u535a\u58eb\u5728\u7f8e\u56fd\u666e\u6e21\u5927\u5b66 (Purdue University) \u83b7\u5f97\u5206\u5b50\u751f\u7269\u5b66\u535a\u58eb\u5b66\u4f4d\uff0c\u5728\u970d\u534e\u5fb7\u4f11\u65af\u533b\u5b66\u7814\u7a76\u6240 (Howard Hughes Medical Institute) \u5b8c\u6210\u535a\u58eb\u540e\u7814\u7a76\u3002\u5979\u66fe\u62c5\u4efb\u7f8e\u4e2d\u533b\u836f\u5f00\u53d1\u534f\u4f1a\uff08SAPA\uff09\u7b2c17\u4efb\u4e3b\u5e2d\uff0cSAPA \u4e2d\u56fd\u4e3b\u5e2d\uff0c\u4e5f\u662fSAPA\u9996\u4f4d\u5973\u4e3b\u5e2d\u3002<\/div>
Dr. Jisong Cui is the co-founder, Chairman, and CEO of Innocare Pharma Limited, InnoCare (SSE code: 688428; HKEx code: 09969) was founded in 2015. It\u2019s a commercial-stage biopharmaceutical high-tech company that focuses on the development of a class of new drugs for the treatment of malignant tumors and autoimmune diseases. The company currently has multiple new drug products in various stages of commercialization, clinical development, and preclinical research. It has branch offices in Beijing, Nanjing, Shanghai, Guangzhou, Hangzhou, Hong Kong, and the United States.<\/div>
Dr. Cui has over 30 years of experience in new drug research and development. She previously worked at Merck in the United States for 14 years, holding positions such as Chair of the Early Cardiovascular Drug Development Department.<\/div>
Dr.Cui obtained her Ph.D. in molecular biology from Purdue University and completed a postdoctoral fellowship at the Howard Hughes Medical Institute. Dr. Cui served as the 17th President of the Sino-American Pharmaceutical Association (SAPA) President of SAPA China, and the first female President of SAPA.<\/div>","name":"\u5d14\u9701\u677e","phone":null,"company":"\u8bfa\u8bda\u5065\u534e","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202310\/28\/87a7d6747bafff53a71ebfbdbc88e98d.png","professional":1})">
崔霁松 - 联合创始人、董事长兼CEO
诺诚健华
\u8881\u94a7\u745b\u4e8e1982\u5e74\u5728\u4e2d\u56fd\u4e0a\u6d77\u590d\u65e6\u5927\u5b66\u83b7\u5f97\u672c\u79d1\u5b66\u4f4d\uff0c 1989 \u5e74\u83b7\u5f97\u54c8\u4f5b\u5927\u5b66\u795e\u7ecf\u79d1\u5b66\u535a\u58eb\u5b66\u4f4d\u3002\u8881\u535a\u58eb\u7684\u535a\u58eb\u8bba\u6587\u662f\u5728\u9ebb\u7701\u7406\u5de5\u5b66\u9662 H. R. Horvitz \u5b9e\u9a8c\u5ba4\u5b8c\u6210\u7684\u30021992 \u5e74\uff0c\u5979\u88ab\u54c8\u4f5b\u5927\u5b66\u533b\u5b66\u9662\u4efb\u547d\u4e3a\u52a9\u7406\u6559\u6388\uff0c\u5e76\u6210\u4e3a\u9ebb\u7701\u603b\u533b\u9662\u5fc3\u8840\u7ba1\u7814\u7a76\u4e2d\u5fc3\u7684\u9996\u5e2d\u7814\u7a76\u5458\u3002\u5979\u4e8e 1996 \u5e74\u52a0\u5165\u54c8\u4f5b\u5927\u5b66\u533b\u5b66\u9662\u7ec6\u80de\u751f\u7269\u5b66\u7cfb\uff0c\u5e76\u4e8e 2000 \u5e74\u88ab\u4efb\u547d\u4e3a\u7ec6\u80de\u751f\u7269\u5b66\u6559\u6388\u30022014\u5e74,\u83b7\u5f97\u54c8\u4f5b\u5927\u5b66ElizabethD.Hay\u6559\u6388\u79f0\u53f7\u3002\uff08\u8be5\u6559\u6388\u804c\u4f4d\u662f\u4e3a\u4e86\u7eaa\u5ff5\u54c8\u4f5b\u5927\u5b66\u533b\u5b66\u9662\u5386\u53f2\u4e0a\u7b2c\u4e00\u4f4d\u5973\u6027\u6b63\u6559\u6388\u3001\u5df2\u6545\u7684\u4f0a\u4e3d\u838e\u767d-\u6d77\u6559\u6388\uff08Elizabeth D. Hay\uff09\u3002\uff09\u8881\u535a\u58eb\u4e8e2020\u5e74\u56de\u56fd\uff0c\u52a0\u5165\u4e0a\u6d77\u6709\u673a\u5316\u5b66\u7814\u7a76\u6240\uff0c\u62c5\u4efb\u751f\u7269\u4e0e\u5316\u5b66\u8de8\u5b66\u79d1\u7814\u7a76\u4e2d\u5fc3\u4e3b\u4efb\u3002<\/div>
\u8881\u535a\u58eb\u662f\u7ec6\u80de\u6b7b\u4ea1\u9886\u57df\u7684\u5148\u9a71\u548c\u6709\u5f71\u54cd\u529b\u7684\u9886\u5bfc\u8005\u3002\u5979\u53d1\u8868\u7684254\u7bc7\u8bba\u6587\u88ab\u9ad8\u5ea6\u5f15\u7528\uff0c\u603b\u5f15\u7528\u6b21\u6570\u8d85\u8fc711.6\u4e07\u6b21\uff08H\u6307\u6570133\uff09\u3002\u5728\u7ec6\u80de\u51cb\u4ea1\uff08apoptosis\uff09\u548c\u7a0b\u5e8f\u6027\u7ec6\u80de\u574f\u6b7b\uff08necroptosis\uff09\u7684\u5de5\u4f5c\u4e2d\u505a\u51fa\u4e86\u91cc\u7a0b\u7891\u5f0f\u7684\u53d1\u73b0\u3002\u5979\u53d1\u73b0\u4e86\u54fa\u4e73\u52a8\u7269\u7684\u534a\u80f1\u5929\u51ac\u9176\uff08caspases\uff09\uff0c\u5f15\u9886\u4e86\u7ec6\u80de\u51cb\u4ea1\u7814\u7a76\u7684\u5206\u5b50\u65f6\u4ee3\u3002\u5979\u5229\u7528\u5316\u5b66\u751f\u7269\u5b66\u8bc1\u660e\u4e86\u53ef\u8c03\u63a7\u7684\u7ec6\u80de\u574f\u6b7b\u65b9\u5f0f\uff0c\u5373\u7a0b\u5e8f\u6027\u7ec6\u80de\u574f\u6b7b\uff08necroptosis\uff09\uff0c\u5728\u4eba\u7c7b\u708e\u75c7\u6027\u548c\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\u4e2d\u7684\u5b58\u5728\u548c\u91cd\u8981\u6027\uff0c\u5e76\u63ed\u793a\u4e86RIPK1\u4f5c\u4e3anecroptosis\u7684\u5173\u952e\u4ecb\u5bfc\u56e0\u5b50\u7684\u4f5c\u7528\u3002\u7531\u8881\u535a\u58eb\u9996\u6b21\u53d1\u73b0\u7684 RIPK1 \u6291\u5236\u5242\u5df2\u8fdb\u5165\u4eba\u4f53\u4e34\u5e8a\u8bd5\u9a8c\u9636\u6bb5\uff0c\u7528\u4e8e\u6cbb\u7597\u5168\u7403\u8303\u56f4\u5185\u7684\u4eba\u7c7b\u708e\u75c7\u548c\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\uff0c\u5982\u808c\u840e\u7f29\u6027\u810a\u9ad3\u4fa7\u7d22\u786c\u5316\u75c7\uff08ALS\uff09\u548c\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\uff08AD\uff09\u3002\u8881\u535a\u58eb\u7684\u6210\u5c31\u83b7\u5f97\u4e86\u8bb8\u591a\u5956\u9879\uff0c\u5305\u62ec\u4e73\u817a\u764c\u7814\u7a76\u521b\u65b0\u5956\u3001\u7f8e\u56fd\u56fd\u7acb\u536b\u751f\u7814\u7a76\u9662\u9662\u957f\u5148\u950b\u5956\u3001\u5b89\u6377\u4f26\u79d1\u6280\u601d\u60f3\u9886\u8896\u5956\u4ee5\u53ca\u4e2d\u56fd\u65c5\u7f8e\u79d1\u6280\u534f\u4f1a\u9881\u53d1\u7684\u6770\u51fa\u79d1\u5b66\u5bb6\u5956\u3002\u5979\u662f\u7f8e\u56fd\u56fd\u5bb6\u79d1\u5b66\u9662\u9662\u58eb\u3001\u7f8e\u56fd\u827a\u672f\u4e0e\u79d1\u5b66\u9662\u9662\u58eb\u548c\u7f8e\u56fd\u79d1\u5b66\u4fc3\u8fdb\u4f1a\u9662\u58eb\u3002<\/div>
Junying Yuan received her undergraduate degree from Fudan University, Shanghai, China, in 1982 and her Ph.D. in Neuroscience from Harvard University in 1989. Dr. Yuan carried out her Ph.D. thesis work at the Massachusetts Institute of Technology in the laboratory of H. R. Horvitz. She was first appointed as Assistant Professor at Harvard Medical School in 1992, when she became a Principal Investigator of the Cardiovascular Research Center at Massachusetts General Hospital. She joined the Department of Cell Biology in 1996 and was appointed a Professor of Cell Biology at Harvard Medical School in 2000. In 2014, Dr. Yuan was appointed as Elizabeth D. Hay Professor of Cell Biology, a Professorship honors the late Professor Elizabeth D. Hay, the first female full professor in the history of Harvard Medical School. Dr. Yuan returned to China in 2020 and joined Shanghai Institute of Organic Chemistry as the Director of Interdisciplinary Research Center on Biology and Chemistry.<\/div>
Dr. Yuan is a pioneer and an influential leader in the cell death field. Her 254 published papers have been highly cited with collective citations of more than 116,000 times (H index 133). Dr. Yuan made transformative discoveries on two distinct forms of cell death, apoptosis and necroptosis in mammalian cells. Her discovery of mammalian caspases led to a molecular era in apoptosis research. She used chemical biology to demonstrate the existence and significance of a regulated necrosis mechanism, termed necroptosis, in human inflammatory and neurodegenerative diseases and the role of RIPK1 as a key mediator of necroptosis. RIPK1 inhibitors, first discovered and described by Dr. Yuan, have been advanced into human clinical trials for the treatment of human inflammatory and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), and Alzheimer\u2019s disease (AD) worldwide. Dr. Yuan\u2019s accomplishments have been honored by many awards including the Innovator Award for Breast Cancer Research, NIH Director\u2019s Pioneer award and Agilent Techno<\/div>","name":"\u8881\u94a7\u745b","phone":null,"company":"\u4e2d\u56fd\u79d1\u5b66\u9662\u4e0a\u6d77\u6709\u673a\u5316\u5b66\u7814\u7a76\u6240\u751f\u7269\u4e0e\u5316\u5b66\u4ea4\u53c9\u7814\u7a76\u4e2d\u5fc3","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202310\/11\/e6017d022916c99e185049f8c5aedd66.png","professional":1})">
袁钧瑛 - 主任
中国科学院上海有机化学研究所生物与化学交叉研究中心
\u674e\u6587\u8f89\uff0c\u535a\u58eb\uff0c\u5317\u4eac\u751f\u547d\u79d1\u5b66\u7814\u7a76\u6240\u8d44\u6df1\u7814\u7a76\u5458\u3002<\/div>
\u674e\u6587\u8f89\u535a\u58eb\u5b9e\u9a8c\u5ba4\u7684\u7814\u7a76\u5174\u8da3\u96c6\u4e2d\u4e8e\u91cd\u8981\u75c5\u6bd2\u611f\u67d3\u7684\u5206\u5b50\u673a\u5236\u53ca\u5176\u9632\u6cbb\u3002\u8fd1\u5e74\u6765\uff0c\u4e3b\u8981\u81f4\u529b\u4e8e\u4e59\u809d\u75c5\u6bd2\uff08HBV\uff09\u7814\u7a76\u3002\u4e59\u578b\u809d\u708e\u662f\u5371\u5bb3\u4eba\u7c7b\u5065\u5eb7\u7684\u4e25\u91cd\u4f20\u67d3\u75c5\uff0c\u5168\u7403\u4f30\u8ba1\u6709HBV\u611f\u67d3\u80052.4\u4ebf\u4eba\uff0c\u5176\u4e2d\u6211\u56fd\u7ea6\u67099300\u4e07\u4eba\uff0c\u6162\u6027HBV\u611f\u67d3\u662f\u5bfc\u81f4\u809d\u786c\u5316\u3001\u809d\u764c\u7684\u91cd\u8981\u75c5\u56e0\u3002\u4e01\u578b\u809d\u708e\u75c5\u6bd2\uff08HDV\uff09\u662fHBV\u7684\u536b\u661f\u75c5\u6bd2,\u5728\u6240\u6709HBV\u611f\u67d3\u8005\u4e2d\uff0c\u7ea6\u67091500\u4e07\u4eba\u540c\u65f6\u611f\u67d3HDV\u3002<\/div>
\u674e\u6587\u8f89\u535a\u58eb\u5e26\u9886\u56e2\u961f\u53d1\u73b0HBV\u53caHDV\u611f\u67d3\u809d\u7ec6\u80de\u7684\u5173\u952e\u53d7\u4f53\u662f\u94a0\u79bb\u5b50-\u725b\u78fa\u80c6\u9178\u5171\u8f6c\u8fd0\u86cb\u767d\uff08NTCP\uff09\uff0c\u5e76\u83b7\u5f972021\u5e74\u5168\u7403\u4e59\u809d\u7814\u7a76\u9886\u57df\u6700\u9ad8\u8363\u8a89\u2014\u2014\u5df4\u9c81\u514b\u00b7\u5e03\u9686\u4f2f\u683c\u5956\uff1b\u7a33\u5b9a\u8868\u8fbe\u4ebaNTCP\u7684HepG2\u7ec6\u80de\u7cfb(HepG2-NTCP)\u5df2\u6210\u4e3aHBV\u76f8\u5173\u57fa\u7840\u75c5\u6bd2\u5b66\u7814\u7a76\u548c\u6297\u75c5\u6bd2\u836f\u7269\u7814\u53d1\u7684\u91cd\u8981\u5e73\u53f0\u3002<\/div>
\u76ee\u524d\uff0c\u5bf9\u4e59\u809d\u611f\u67d3\u7684\u79d1\u5b66\u7814\u7a76\u53ca\u836f\u7269\u5f00\u53d1\u5df2\u8fdb\u5165\u4e00\u4e2a\u5145\u6ee1\u751f\u673a\u7684\u65b0\u65f6\u4ee3\u3002\u674e\u6587\u8f89\u535a\u58eb\u5b9e\u9a8c\u5ba4\u7efc\u5408\u8fd0\u7528\u75c5\u6bd2\u5b66\uff0c\u751f\u7269\u5316\u5b66\uff0c\u514d\u75ab\u5b66\uff0c\u5316\u5b66\u751f\u7269\u5b66\u7b49\u591a\u5b66\u79d1\u65b9\u6cd5\u6df1\u5165\u5256\u6790HBV\u53caHDV\u611f\u67d3\u8fc7\u7a0b\u7684\u5206\u5b50\u57fa\u7840\uff0c\u4ee5\u5e2e\u52a9\u7406\u89e3\u5176\u75c5\u7406\u673a\u5236\u3002\u56e2\u961f\u5e0c\u671b\u7814\u53d1\u65b0\u7684\u6297\u75c5\u6bd2\u836f\u7269\uff0c\u4e3a\u6700\u7ec8\u6709\u6548\u89e3\u9664\u60a3\u8005\u7684\u75c5\u75db\u800c\u52aa\u529b\u3002\u6b64\u5916\uff0c\u674e\u6587\u8f89\u535a\u58eb\u56e2\u961f\u4e5f\u4e0e\u76f8\u5173\u5b9e\u9a8c\u5ba4\u5408\u4f5c\u7814\u7a76NTCP\/\u80c6\u9178\u7b49\u5206\u5b50\u5728\u611f\u67d3\u53ca\u673a\u4f53\u4ee3\u8c22\u8fc7\u7a0b\u4e2d\u7684\u76f8\u5173\u4f5c\u7528\u3002<\/div>
\u674e\u6587\u8f892001\u5e74\u83b7\u5f97\u4e2d\u56fd\u534f\u548c\u533b\u79d1\u5927\u5b66\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662 \u75c5\u539f\u751f\u7269\u5b66\u535a\u58eb\u5b66\u4f4d\uff0c2001.9-2004.5\u5728\u54c8\u4f5b\u5927\u5b66\u533b\u5b66\u9662\u505a\u535a\u540e\uff0c2004.6-2007.9\u62c5\u4efb\u54c8\u4f5b\u5927\u5b66\u533b\u5b66\u9662Instructor\uff0c2007.10-2015.2\u62c5\u4efb\u5317\u4eac\u751f\u547d\u79d1\u5b66\u7814\u7a76\u6240\u7814\u7a76\u5458\uff0c2015.3\u81f3\u4eca\u4e3a\u5317\u4eac\u751f\u547d\u79d1\u5b66\u7814\u7a76\u6240\u8d44\u6df1\u7814\u7a76\u5458\u3002<\/div>
Wenhui Li, Senior Researcher of National Institute of Biological Sciences\uff0cBeijing<\/span><\/div>
 <\/span><\/div>
Dr.Wenhui Li's laboratory focuses on the molecular mechanisms of important viral infections and their prevention and treatment. In recent years, they have primarily dedicated their research to the study of Hepatitis B virus(HBV). Hepatitis B is a severe infectious disease that poses a significant threat to human health, with an estimated 240 million HBV-infected individuals worldwide, including approximately 93 million in China. Chronic HBV infection is a major cause of liver cirrhosis and liver cancer. Hepatitis D virus (HDV) is a satellite virus of HBV, and approximately 15 million individuals are co-infected with HDV among all HBV-infected individuals.<\/span><\/div>
 <\/span><\/div>
Dr. Wenhui Li, along with his team, discovered that the key receptor for HBV and HDV infection in liver cells is the sodium taurocholate cotransporting polypeptide (NTCP). This groundbreaking discovery earned them the prestigious 2021 Baruch S. Blumberg Prize, the highest recognition in the global HBV research field. The stable expression of human NTCP in the Human hepatocellular carcinomas (HepG2-NTCP) has become a crucial platform for studying HBV-related basic virology and developing antiviral drugs.<\/span><\/div>
 <\/span><\/div>
Currently, scientific research and drug development for hepatitis B infection have entered a vibrant new era. Dr.Wenhui Li's laboratory employs an integrated approach, encompassing virology, biochemistry, immunology, chemical biology, and other disciplines, to delve into the molecular basis of HBV and HDV infection processes, aiding in the understanding of their pathological mechanisms. The team aspires to develop novel antiviral drugs, striving to ultimately alleviate patients' suffering effectively. Additionally, Dr. Li Wenhui's team collaborates with relevant laboratories to investigate the roles of molecules such as NTCP\/bile acids in infection and metabolic processes within the body.<\/span><\/div>
 <\/span><\/div>
In 2001, Dr. Li Wenhui obtained his Ph.D. degree in Pathogenic Biology from Peking Union Medical College, Chinese Academy of Medical Sciences. From September 2001 to May 2004, he conducted postdoctoral research at Harvard Medical School. Following that, he served as an Instructor at Harvard Medical School from June 2004 to September 2007. From October 2007 to February 2015, he held the position of Researcher at the Beijing Institute of Life Sciences. Since March 2015, he has been a Senior Researcher at the Beijing Institute of Life Sciences.<\/span><\/div>

<\/div>

<\/div>","name":"\u674e\u6587\u8f89","phone":null,"company":"\u5317\u4eac\u751f\u547d\u79d1\u5b66\u7814\u7a76\u6240","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202311\/09\/35b05520c2afb67205270e0f3a74e8b4.png","professional":1})">
李文辉 - 资深研究员
北京生命科学研究所
Amanda\u5728\u5b8c\u6210\u4e86\u5728CSIRO\u6750\u6599\u79d1\u5b66\u4e0e\u5de5\u7a0b\u90e8\u95e8\u7684\u7eb3\u7c73\u79d1\u5b66\u535a\u58eb\u540e\u7814\u7a76\u5de5\u4f5c\u4e4b\u540e\uff0c\u4e8e2014\u5e74\u52a0\u5165Springer Nature\uff0c\u62c5\u4efb\u81ea\u7136\u7814\u7a76\u5b9a\u5236\u5a92\u4f53\u56e2\u961f\uff08NRCM\uff09\u7684\u526f\u7f16\u8f91\u3002\u81ea2022\u5e74\u521d\u4ee5\u6765\uff0c\u5979\u4e00\u76f4\u62c5\u4efb\u4e9a\u592a\u5730\u533a\u7684\u9996\u5e2d\u7f16\u8f91\uff0c\u8d1f\u8d23\u7ba1\u7406NRCM\u4e9a\u592a\u56e2\u961f\u7684\u7f16\u8f91\u5de5\u4f5c\u3002<\/div>
After completing a nanoscience-focussed postdoctoral fellowship at CSIRO Materials Science and Engineering, Amanda joined Springer Nature as an Associate Editor in 2014 in the Nature Research Custom Media team (NRCM). She has managed the NRCM Asia-Pacific team of editors as Chief Editor, APAC, Nature Research Custom Media, since the beginning of 2022.<\/div>","name":"Amanda","phone":null,"company":"\u81ea\u7136\u79d1\u7814\u5b9a\u5236\u670d\u52a1","img_url":"https:\/\/yaorongyun-public.oss-cn-shanghai.aliyuncs.com\/images\/conference_guest_images\/202311\/13\/3663dea5b3386d7b242e0bcf7d7668e8.jpg","professional":1})">
Amanda - 亚太区总编辑
自然科研定制服务
展开收起

大会日程

  • 11月19日
大会议程
嘉宾
嘉宾
嘉宾
Lieping Chen - 教授
耶鲁大学
嘉宾
陈冰 - 中国副总裁
阿斯利康
嘉宾
李宁 - 副院长
中国医学科学院肿瘤医院
嘉宾
轻松一刻 - 休息一下
商务交流
嘉宾
Clive Svendsen - 主任
西达-赛奈再生医学研究所
嘉宾
Lieping Chen - 教授
耶鲁大学
李宁 - 副院长
中国医学科学院肿瘤医院
陈冰 - 中国副总裁
阿斯利康
李锋 - 董事长兼总经理
天广实生物
王兴利 - 执行总裁
复星医药
嘉宾
嘉宾
Joshua Brody - 副教授
美国西奈山伊坎医学院
嘉宾
Anna Cereseto - 首席研究员、系副主任
意大利特伦托大学分子生物学实验室
嘉宾
Antonio Bertoletti - 传染病专家
杜克-新加坡国立大学医学院
嘉宾
崔霁松 - 联合创始人、董事长兼CEO
诺诚健华
嘉宾
袁钧瑛 - 主任
中国科学院上海有机化学研究所生物与化学交叉研究中心
嘉宾
轻松一刻 - 休息一下
商务交流
嘉宾
Antonio Bertoletti - 传染病专家
杜克-新加坡国立大学医学院
袁钧瑛 - 主任
中国科学院上海有机化学研究所生物与化学交叉研究中心
崔霁松 - 联合创始人、董事长兼CEO
诺诚健华
李文辉 - 资深研究员
北京生命科学研究所
Amanda Rider - 亚太区总编辑
自然科研定制服务

主办单位

北京市昌平区人民政府
15857107124

承办单位

未来科学城管委会（生命园管委会）
15857107124
北京中关村生命科学园发展有限责任公司
15857107124
Nature Portfolio
15857107124
北京中关村生命科学园生物医药科技孵化器有限公司
15857107124
北京昌平科技园发展有限公司
15857107124
药融圈
15857107124

商务合作

张玲 - 商务总监
15005862516

参会联系

郑王曦 - 会务组
15857107124
蒋晓华 - 会务组
13551362642

年度会议日程

2025年
  • 2001年
  • 2002年
  • 2003年
  • 2004年
  • 2005年
  • 2006年
  • 2007年
  • 2008年
  • 2009年
  • 2010年
  • 2011年
  • 2012年
  • 2013年
  • 2014年
  • 2015年
  • 2016年
  • 2017年
  • 2018年
  • 2019年
  • 2020年
  • 2021年
  • 2022年
  • 2023年
  • 2024年
  • 2025年
  • 2026年
  • 2027年
  • 2028年
共21场
共103场
共79场
共69场
共83场
共29场
共36场
共56场
tyc7111cc太阳成集团企业版
50亿+条医药数据随时查
7天免费试用
体验产品

相关报告

更多
  • 2024年医药企业综合实力排行榜

    报告日期：2025-05-23页数 28

  • 中国临床试验趋势与国际多中心临床展望

    报告日期：2025-05-15页数 34

  • 中国带状疱疹疫苗行业分析报告

    报告日期：2025-05-14页数 33

  • 基于AI大模型的医药知识工程系统部署方案

    报告日期：2025-04-27页数 53

  • 数据透视：中药创新药、经典验方、改良型新药、同名同方的申报、获批、销售情况

    报告日期：2025-04-22页数 39

2023年全国医院销售(全终端)数据

更多
药品名称
销售额(亿元)

全球新药治疗领域统计

更多

临床试验趋势